ARMISTICE CAPITAL, LLC - 15 Jun 2021 Form 4 Insider Report for ReShape Weightloss Inc. (RSLS)

Reporting relationship
10%+ Owner
Issuer ticker
RSLS
Reported as of
15 Jun 2021
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
22 Jun 2021, 08:33:40 UTC
Prior SEC filing
18 May 2021
Next SEC filing
22 Jun 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member

Key filing fact

ARMISTICE CAPITAL, LLC filed Form 4 for ReShape Weightloss Inc. (RSLS) on 22 Jun 2021.

Key facts

  • This page summarizes ARMISTICE CAPITAL, LLC's Form 4 filing for ReShape Weightloss Inc. (RSLS).
  • 14 reported transactions and 12 derivative rows are listed below.
  • Accepted by SEC: 22 Jun 2021, 08:33.

Change

  • Previous filing in this sequence was filed on 18 May 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RSLS transaction

Common Stock

Other

Transaction value
Shares
-5,330,277
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Footnotes
F1, F2
RSLS transaction

Common Stock

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RSLS transaction Derivative

Series A Warrants

Other

Transaction value
Shares
-2,625,000
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,625,000
Exercise price
$0.0220
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series A Warrants

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
0
Exercise price
$0.0220
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series E Warrants

Other

Transaction value
Shares
-2,625,000
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,625,000
Exercise price
$0.0500
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series E Warrants

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
0
Exercise price
$0.0500
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series G Warrants

Other

Transaction value
Shares
-1,200,000
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,200,000
Exercise price
$3.25
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series G Warrants

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
0
Exercise price
$3.25
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series G Warrants

Other

Transaction value
Shares
-1,200,000
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,200,000
Exercise price
$3.70
Footnotes
F2, F3, F4
RSLS transaction Derivative

Series G Warrants

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
0
Exercise price
$3.70
Footnotes
F2, F3, F4
RSLS transaction Derivative

Warrant

Other

Transaction value
Shares
-4,000,000
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,000,000
Exercise price
$3.50
Footnotes
F2, F3, F4
RSLS transaction Derivative

Warrant

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
0
Exercise price
$3.50
Footnotes
F2, F3, F4
RSLS transaction Derivative

Warrant

Other

Transaction value
Shares
-1,000,000
Change %
-100%
Price
Shares after
0
Date
15 Jun 2021
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,000,000
Exercise price
$3.50
Footnotes
F2, F3, F4
RSLS transaction Derivative

Warrant

Other

Transaction value
$0
Shares
0
Change %
Price
$0.000000*
Shares after
0
Date
15 Jun 2021
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
0
Exercise price
$3.50
Footnotes
F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

ARMISTICE CAPITAL, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

These reported securities were disposed of pursuant to a merger between the Issuer, Obalon Therapeutics, Inc. ("Obalon") and Optimus Merger Sub, a wholly owned subsidiary of Obalon ("Merger Sub") that became effective on June 15, 2021 (the "Merger"). As a result of the Merger, Obalon was renamed ReShape Lifesciences Inc. ("Combined Company") and all of the reported securities were converted into securities of the Combined Company pursuant to the conversion ratio and all other terms contained in the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Obalon, and Merger Sub (incorporated by reference to Exhibit 2.1 the Form 8-K filed by the Issuer with the SEC on June 15, 2021) (the "Merger Agreement").

Footnote F2

The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F3

These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement.

Footnote F4

These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .